Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

NCT00303472 ·Status: COMPLETED ·Phase: PHASE2

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

NCT01165996 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Aminopterin in Treating Patients With Refractory Leukemia

NCT00003305 ·Status: COMPLETED ·Phase: PHASE2

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

NCT00903422 ·Status: COMPLETED ·Phase: PHASE1

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

NCT02093429 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

NCT02002936 ·Status: COMPLETED ·Phase: PHASE1

Erlotinib Study for Myelodysplastic Syndrome (MDS)

NCT00977548 ·Status: COMPLETED ·Phase: PHASE2

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

NCT00321711 ·Status: COMPLETED ·Phase: PHASE2

Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT00614523 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)

NCT00413114 ·Status: COMPLETED ·Phase: PHASE2

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome

NCT00570375 ·Status: WITHDRAWN ·Phase: PHASE2

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

NCT04187703 ·Status: RECRUITING ·Phase: EARLY_PHASE1

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

NCT03957876 ·Status: TERMINATED ·Phase: PHASE2

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

NCT01822691 ·Status: COMPLETED ·Phase: PHASE2

Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

NCT04478123 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT01795924 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

NCT01513317 ·Status: TERMINATED ·Phase: PHASE2

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867 ·Status: RECRUITING ·Phase: PHASE2

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

NCT07107126 ·Status: RECRUITING ·Phase: PHASE1

Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

NCT00493571 ·Status: COMPLETED ·Phase: PHASE1

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

NCT02363491 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Multiple Ascending Dose of BMS-911543

NCT01236352 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

NCT03495167 ·Status: COMPLETED ·Phase: PHASE1

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

NCT01873703 ·Status: COMPLETED ·Phase: PHASE2